Sharp Therapeutics Corp. (TSXV:SHRX)

Sharp Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022
Period Ending	Jun 30, 2024	Dec 31, 2023	Dec 31, 2022
Net Income	-4.91	-3.56	-3.88
Depreciation & Amortization	0.1	0.11	0.13
Stock-Based Compensation	0.01	0.03	0.08
Other Operating Activities	2.04	1.3	1.47
Change in Accounts Payable	0.58	0.18	0.16
Change in Other Net Operating Assets	-0	-0.02	0
Operating Cash Flow	-2.18	-1.96	-2.05
Capital Expenditures	-0.01	-0.01	-
Investing Cash Flow	-0.01	-0.01	-
Long-Term Debt Repaid	-	-0.2	-0.18
Net Debt Issued (Repaid)	-0.23	-0.2	-0.18
Issuance of Common Stock	2.38	2.38	1.2
Financing Cash Flow	2.12	2.18	1.02
Net Cash Flow	-0.07	0.21	-1.03
Free Cash Flow	-2.19	-1.97	-2.05
Free Cash Flow Per Share	-15.76	-14.17	-14.77
Levered Free Cash Flow	-	-1.23	-
Unlevered Free Cash Flow	-	-1.12	-
Change in Net Working Capital	-	-0.16	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.